Paper Details

  1. Home
  2. Paper Details

Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.

Author: AssoumouLambert, AznarEsther, BéniguelLydie, CardonFanny, CostagliolaDominique, CrespoManuel, DelaugerreConstance, DialloAlpha, IzopetJacques, LancarRémi, LelièvreJean-Daniel, LévyYves, MeybeckAgnès, MolinaJean-Michel, PeytavinGilles, PulidoFederico, TambussiGiuseppe

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study found that adding maraviroc to standard combined antiretroviral therapy (c-ART) did not improve clinical outcomes in patients initiating therapy for advanced HIV infection. The study suggests that maraviroc is not beneficial for patients with advanced HIV disease at diagnosis.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Patients diagnosed with advanced HIV infection have a poor prognosis despite initiation of combined antiretroviral therapy (c-ART). OBJECTIVE: To assess the benefit of adding maraviroc, an antiretroviral drug with immunologic effects, to standard c-ART for patients with advanced disease...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.7326/M19-2133

データ提供：米国国立医学図書館（NLM）

Advanced HIV Infection: Finding New Solutions in a Challenging Landscape

Treating advanced HIV infection, where the immune system is severely compromised, presents a unique challenge. This study examined the effectiveness of adding maraviroc, an antiretroviral drug, to the standard treatment regimen for patients with advanced HIV infection. It's like seeking a new path through a rugged terrain, hoping to find a way to better combat the effects of the virus.

Maraviroc: A Promise Unfulfilled?

The results showed that adding maraviroc to the standard treatment did not improve the clinical outcomes for patients with advanced HIV infection. This is a sobering reminder that the battle against HIV is far from over, and new treatment strategies are constantly being sought. It's like discovering that a seemingly promising oasis doesn't hold the water we hoped for, leading us to continue our search for a truly life-giving solution.

The Need for Ongoing Research: A Journey Towards a Cure

The fight against HIV requires a multi-faceted approach, with continuous research to identify new drugs and treatment strategies. This study underscores the importance of exploring different approaches to effectively manage advanced HIV infection. It's like constantly exploring the vast desert, seeking out new paths and possibilities that might lead to a more effective solution for those living with HIV.

Dr.Camel's Conclusion

The journey to a cure for HIV is a long and winding one. This study highlights the need for continued research and innovation, reminding us that the search for effective treatments must never cease. We must continue our exploration of the desert, seeking out new solutions and pushing the boundaries of what's possible.
Date :
  1. Date Completed 2020-08-31
  2. Date Revised 2020-08-31
Further Info :

Pubmed ID

32040959

DOI: Digital Object Identifier

10.7326/M19-2133

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.